Format

Send to

Choose Destination
Nucl Med Mol Imaging. 2017 Jun;51(2):154-160. doi: 10.1007/s13139-016-0451-8. Epub 2016 Oct 6.

Clinical Significance of Pretreatment FDG PET/CT in MIBG-Avid Pediatric Neuroblastoma.

Kang SY1,2, Rahim MK3,4, Kim YI1,2, Cheon GJ1,5,6, Kang HJ7, Shin HY7, Kang KW1,5, Chung JK1,5, Kim EE2,8, Lee DS1,2.

Author information

1
Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Korea.
2
Department of Molecular Medicine and Biopharmaceutical Science, WCU Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea.
3
Fellowship of Koh Chang Soon Program, Seoul National University College of Medicine, Seoul, Korea.
4
Department of Nuclear Medicine, Multan Institute of Nuclear Medicine and Radiotherapy, Nishtar Medical College and Hospital, Multan, Pakistan.
5
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
6
Department of Nuclear Medicine, Seoul National University College of Medicine, 101 Daehangro, Jongro-gu, Seoul, 110-744 Korea.
7
Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
8
Department of Radiological Science, University of California at Irvine, Irvine, CA USA.

Abstract

PURPOSE:

18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging is well known to have clinical significance in the initial staging and response evaluation of the many kinds of neoplasms. However, its role in the pediatric neuroblastoma is not clearly defined. In the present study, the clinical significance of FDG-PET/computed tomography (CT) in 123I- or 131I-metaiodobenzylguanidine (MIBG)-avid pediatric neuroblastoma was investigated.

METHODS:

Twenty patients with neuroblastoma who undertook pretreatment FDG PET/CT at our institute between 2008 and 2015 and showed MIBG avidity were retrospectively enrolled in the present study. Clinical information-including histopathology, and serum markers-and several PET parameters-including SUVmax of the primary lesion (Psuv), target-to-background ratio (TBR), metabolic tumor volume (MTV), and coefficient of variation (CV)-were analyzed. The prognostic effect of PET parameters was evaluated in terms of progression-free survival (PFS).

RESULTS:

Total 20 patients (4.5 ± 3.5 years) were divided as two groups by disease progression. Six patients (30.0 %) experienced disease progression and one patient (5.0 %) died during follow-up period. There were not statistically significant in age, stage, MYCN status, primary tumor size, serum lactate dehydrogenase (LDH), neuron-specific enolase (NSE), and ferritin level between two groups with progression or no progression. However, Psuv (p = 0.017), TBR (p = 0.09), MTV (p = 0.02), and CV (p = 0.036) showed significant differences between two groups. In univariate analysis, PFS was significantly associated with Psuv (p = 0.021) and TBR (p = 0.023).

CONCLUSIONS:

FDG-PET parameters were significantly related with progression of neuroblastoma. FDG-PET/CT may have the potential as a valuable modality for evaluating prognosis in the patients with MIBG-avid pediatric neuroblastoma.

KEYWORDS:

F-18 FDG positron-emission tomography; Neuroblastoma; Pediatrics; Prognosis

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center